2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK Stem Cell/Wnt Neuronal Signaling Cell Cycle/DNA Damage Apoptosis PI3K/Akt/mTOR
  3. EGFR Notch CDK Apoptosis Akt
  4. CP-654577

CP-654577 is a selective ErbB2 inhibitor with an IC50 of 11 nM. CP-654577 downregulates the Notch1 signaling pathway. CP-654577 upregulates p27kip1, reduces the levels of Cyclins D and E, and inhibits G1 phase progression of the cell cycle. CP-654577 induces cell Apoptosis, downregulates activated Akt, and suppresses tumor growth in athymic mice. CP-654577 can be used in breast cancer-related research.

For research use only. We do not sell to patients.

CP-654577

CP-654577 Chemical Structure

CAS No. : 639087-64-2

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

CP-654577 Related Antibodies

Top Publications Citing Use of Products

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

View All CDK Isoform Specific Products:

View All Isoforms
CDK1 CDK2 CDK3 CDK4 CDK5 CDK6 CDK7 CDK8 CDK9 CDK11 CDK12 CDK13 CDK14 CDK16 CDK19 CDC CLK Pho85 CDK10 CDK15 CDK17 CDK18 CDK20 PITSLRE

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

CP-654577 is a selective ErbB2 inhibitor with an IC50 of 11 nM. CP-654577 downregulates the Notch1 signaling pathway. CP-654577 upregulates p27kip1, reduces the levels of Cyclins D and E, and inhibits G1 phase progression of the cell cycle. CP-654577 induces cell Apoptosis, downregulates activated Akt, and suppresses tumor growth in athymic mice. CP-654577 can be used in breast cancer-related research[1][2][3].

IC50 & Target[2]

ErbB2

11 nM (IC50)

EGFR

670 nM (IC50)

In Vitro

CP-654577 (300-1000 nM) reduces Notch1 signaling (measured via CBF reporter activity) in ErbB2-overexpressing SKBR3 breast cancer cells, with 1000 nM causing a 50% reduction in activity[1].
CP-654577 (300-1000 nM; 36 hours post-transfection) does not affect Notch1 (CBF reporter) or Wnt (TOP-luc) signaling in low-ErbB2-expressing MCF-7 breast cancer cells at concentrations of 300 nM and 1000 nM[1].
CP-654577 (6 min) is a selective inhibitor of purified human erbB2 kinase, with 60-fold higher potency against erbB2 (IC50 = 11 nM) than EGFr (IC50 = 670 nM), and shows limited activity against other non-erbB family tyrosine kinases[2].
CP-654577 (0.1-3 μM; 2 h pre-incubation before 15 min EGF stimulation) selectively inhibits erbB2 kinase activity in intact NIH 3T3 cells, potently suppressing EGF-induced phosphotyrosine levels in erbB2/EGFR chimera-transfected cells (to <5% of control at ≥0.3 μM) while only weakly inhibiting EGFR-transfected cells at equivalent concentrations[2].
CP-654577 (24 h) potently inhibits the proliferation of SKBr3 human breast cancer cells with an IC50 of 55 nM after 24 h of exposure[2].
CP-654577 (50 nM-1000 nM; 2 h, 8 h, 12 h, 24 h) induces a concentration-dependent G1 cell-cycle arrest in SKBr3 human breast cancer cells, with marked effects observed at 250 nM and 1000 nM after 8 h, 12 h, and 24 h of exposure[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CP-654577 Related Antibodies

Cell Cycle Analysis[2]

Cell Line: SKBr3 human breast cancer cells
Concentration: 50 nM-1000 nM
Incubation Time: 2 h, 8 h, 12 h, 24 h
Result: Showed no change in cell cycle phase distribution after 2 h of treatment.
Increased the G1 cell population from 62% (control) to 67% (50 nM), 67% (250 nM), and 72% (1000 nM), while decreasing the S phase population from 30% to 26%, 25%, and 22% respectively, with no change in G2/M phase after 8 h.
Increased the G1 cell population from 62% (control) to 76% (50 nM), 84% (250 nM), and 85% (1000 nM), while decreasing the S phase population from 24% to 12%, 4%, and 1% respectively, with no change in G2/M phase after 12 h.
Increased the G1 population to 67% (50 nM), 87% (250 nM), and 93% (1000 nM), while decreasing the S phase population to 27%, 8%, and 2% respectively after 24 h.
In Vivo

CP-654577 (25-100 mg/kg; i.p.; single dose) dose-dependently inhibits erbB2 tyrosine phosphorylation in FRE-erbB2 tumor xenografts, with an ED50 of 43 mg/kg[2].
CP-654577 (12.5-50 mg/kg; i.p.; twice daily; 7 days) dose-dependently inhibits the growth of FRE-erbB2 tumor xenografts, achieving 65% growth inhibition at 50 mg/kg twice daily after 7 days of treatment[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: CD-1 Nu/Nu (female, 3 to 4 weeks old)[2]
Dosage: 25 mg/kg; 37.5 mg/kg; 50 mg/kg; 75 mg/kg; 100 mg/kg
Administration: i.p.; single dose
Result: Reduced erbB2 tyrosine phosphorylation by approximately 32% at 25 mg/kg.
Reduced erbB2 tyrosine phosphorylation by approximately 50% at 37.5 mg/kg.
Reduced erbB2 tyrosine phosphorylation by approximately 50% at 50 mg/kg.
Reduced erbB2 tyrosine phosphorylation by approximately 60% at 75 mg/kg.
Reduced erbB2 tyrosine phosphorylation by approximately 65% at 100 mg/kg.
Achieved an ED50 of 43 mg/kg for reduction of erbB2 tyrosine phosphorylation relative to vehicle controls.
Animal Model: CD-1 Nu/Nu (female, 3 to 4 weeks old)[2]
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: i.p.; twice daily; 7 days
Result: Inhibited FRE-erbB2 tumor growth by 40% at 12.5 mg/kg twice daily on Day 7 post-treatment initiation.
Inhibited FRE-erbB2 tumor growth by 58% at 25 mg/kg twice daily on Day 7 post-treatment initiation.
Inhibited FRE-erbB2 tumor growth by 65% at 50 mg/kg twice daily on Day 7 post-treatment initiation.
Caused no mortality or weight loss in any treatment group.
Molecular Weight

544.66

Formula

C34H32N4O3
CAS No.
SMILES

C(O)[C@H]1[C@]2([C@@]1(CN(CC3=CC=C(C=C3)C4=CC=5C(NC6=CC(OC)=C(OC7=CC=CC=C7)C=C6)=NC=NC5C=C4)C2)[H])[H]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

CP-654577 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

CP-654577639087-64-2CP654577CP 654577EGFRNotchCDKApoptosisAktEpidermal growth factor receptorErbB-1HER1Cyclin dependent kinasePKBProtein kinase BMCF-7 breast cancer cellsErbB2p185erbB2 tyrosine kinaseerbB2 autophosphorylationp27kip1SKBR3 breast cancer cellsNotch1 signalingEGFr tyrosine kinasemitogen-activated protein kinaseretinoblastoma proteinInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CP-654577
Cat. No.:
HY-118900
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.